Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Assets Average (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Assets Average for 11 consecutive years, with $219.7 million as the latest value for Q1 2026.

  • For Q1 2026, Assets Average rose 1925.89% year-over-year to $219.7 million; the TTM value through Mar 2026 reached $219.7 million, up 1925.89%, while the annual FY2023 figure was $48.6 million, 33.55% down from the prior year.
  • Assets Average hit $219.7 million in Q1 2026 for Crescent Biopharma, up from $189.3 million in the prior quarter.
  • Across five years, Assets Average topped out at $219.7 million in Q1 2026 and bottomed at $10.8 million in Q1 2025.
  • Average Assets Average over 5 years is $77.9 million, with a median of $60.4 million recorded in 2022.
  • Year-over-year, Assets Average crashed 72.72% in 2025 and then soared 1925.89% in 2026.
  • Crescent Biopharma's Assets Average stood at $53.9 million in 2022, then dropped by 8.59% to $49.3 million in 2023, then tumbled by 59.28% to $20.1 million in 2024, then skyrocketed by 843.65% to $189.3 million in 2025, then rose by 16.08% to $219.7 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $219.7 million, $189.3 million, and $147.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.